Skip to main content

Table 1 Baseline characteristics of patients with type 2 diabetes as divided into poor and good glycemic control

From: Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control

 

Poor glycemic control

Good glycemic control

P value

Number

23

13

-

Age (years)

59.7 ± 13.2 (31-86)

64.7 ± 13.2 (41-86)

0.287

Sex (male:female)

9:14

5:08

-

BMI (kg/m2)

23.8 ± 2.8

21.6 ± 4.5

0.516

Duration of diabetes (years)

6.7 ± 4.3 (1-15)

5.2 ± 4.3 (1-13.4)

0.433

Systolic blood pressure (mmHg)

126.2 ± 18 (100-170)

134.4 ± 16 (110-150)

0.251

Diastolic blood pressure (mmHg)

79.1 ± 8.9 (60-90)

76.7 ± 7.1 (70-90)

0.582

HbA1C (%)

9.2 ± 1.4 (7-12.2)

6.2 ± 0.5 (5.3-6.6)

< 0.001

FBS (mmol/l)

8.9 ± 1.8 (5.8-11.8)

6.7 ± 0.8 (5.6-8.2)

< 0.001

Total cholesterol (mg/dl)

175.9 ± 31.9 (134-242)

191.8 ± 42.6 (148-264)

0.314

LDL cholesterol (mg/dl)

98.6 ± 25.3 (61-146)

125 ± 41.9 (76-215)

0.936

HDL cholesterol (mg/dl)

51.8 ± 12.8 (35-75)

48 ± 13.6 (32-73)

0.977

Triglyceride (mg/dl)

137.8 ± 70 (54-310)

218.5 ± 121.5 (100-340)

0.124

Therapy

   

   Statin [n (%)]

15 (65)

7 (53)

-

   ACEI/ARB [n (%)]

4 (17)

3 (23)

-

   Aspirin [n (%)]

1 (4)

1 (7)

-

   OHA [n (%)]

20 (87)

10 (77)

-

   Insulin [n (%)]

1 (4)

1 (7)

-

   OHD + Insulin [n (%)]

2 (8)

-

-

  1. Data are presented as mean ± SD, percentage or median (interquartile range); ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body-mass index; FBS, fasting blood sugar; HbA1C, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OHA, oral hypoglycemic agent.